DOCSLIB.ORG

Ubc Department of Medicine 2005 Annual Report

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Ubc Department of Medicine 2005 Annual Report UBC DEPARTMENT OF MEDICINE 2005 ANNUAL REPORT TABLE OF CONTENTS MESSAGE FROM DR. GRAYDON MENEILLY….….….….………………………………3 MISSION STATEMENT.……………………………………………………...……………….7 ORGANIZATION CHART.………………………………………………...………………….9 UBC DEPARTMENT OF MEDICINE COMMITTEE STRUCTURES………………..…11 UBC DEPARTMENT OF MEDICINE ADMINISTRATIVE OFFICE...………………….13 UBC DEPARTMENT OF MEDICINE COMMITTEES..………………………………….. 15 Department Heads, Associate Heads, UBC Division Heads, Educational Program Directors & Associate Directors.………………………………………… 17 Research………………………………………………………………………………………….19 Committee for Appointments, Reappointments, Promotion and Tenure.………………………. 21 Teaching Effectiveness Office.…………………………………………………………………..25 DIVISION REPORTS.…………………………………………………………………………27 Allergy & Immunology.………………………………………………………………………… 29 Cardiology.……………………………………………………………………………………….33 Critical Care Medicine.…………………………………………………………………………..45 Dermatology.……………………………………………………………………………………. 49 Endocrinology.………………………………………………………………………………….. 55 Gastroenterology.…………………………………………………………………………….…. 59 General Internal Medicine.……………………………………………………………………… 63 Geriatric Medicine.……………………………………………………………………………… 67 Hematology.…………………………………………………………………………………….. 71 Infectious Diseases.………………………………………………………………………………75 Medical Oncology.……………………………………………………………………………… 81 Nephrology.…………………………………….……………………………………………..… 87 Neurology.……………………………………….…………………………………………….... 93 Occupational Medicine…………………………………………………………………………109 Physical Medicine & Rehabilitation.…………………………………………………………...113 Respiratory Medicine.…………………………………………………………………………..117 Rheumatology.………………………………………………………………………………….121 EDUCATIONAL PROGRAMS.…………………………………………………………….. 127 Clinical Investigator Program.…………………………………………………………………. 129 Continuing Medical Education Program..……………….…………………………..………… 135 Graduate Studies Program in Experimental Medicine….……………………………………… 137 HIV/AIDS Research Program..…………………………………………………………………141 Postgraduate Education Program.……………………………………………………………… 147 Undergraduate Education Program.……………………………………………………………. 151 PUBLICATIONS….………………………………………………………………………….. 153 GRANTS AND RESEARCH AWARDS.………………………………………………..….. 208 UBC Department of Medicine Page 1 Annual Report 2005 Message From Dr Graydon Meneilly Graydon S. Meneilly, MD, FRCPC Eric W. Hamber Professor & Head UBC Department of Medicine I am pleased to provide this overview for the 2005 annual report on behalf of the UBC Department of Medicine. This report is also available on the internet at www.medicine.ubc.ca Overview The UBC Department of Medicine provides research, teaching and clinical services related to the nature, cause and prevention of adult diseases. We are the largest Department in the Faculty of Medicine and we consist of 18 divisions: Allergy and Immunology, Cardiology, Community Internal Medicine, Critical Care, Dermatology, Endocrinology, Gastroenterology, Geriatric Medicine, Internal Medicine, Hematology, Infectious Diseases, Medical Oncology, Nephrology, Neurology, Occupational Medicine, Physical Medicine and Rehabilitation, Respiratory Medicine and Rheumatology. Members As you read through this document you encounter the many different aspects of our Department and the things we have achieved over the past year. I would like to take this opportunity to highlight some of the many wonderful accomplishments of our members. In particular I would like to highlight the contributions of Dr Paul Man, Associate Head of Medicine at UBC and Chair, Department of Medicine at Providence Health Care. He is absolutely integral to the function of the Department and all of our strategic initiatives. Recruitment and retention are a large part of our business. We have appointed 4 Professors, 3 Associate Professors, 1 Assistant Professor, 2 Clinical Professors, 1 Clinical Associate Professor, 21 Clinical Assistant Professors, 8 Clinical Instructors, 1 Adjunct Professor and 1 Associate Member. We have promoted 23 Faculty members effective July 1, 2005. UBC Department of Medicine Page 3 Annual Report 2005 Our faculty received 5 CIHR Scholarship/Scientist awards, 16 Michael Smith Scholarships/Scientist awards, 7 CRC Scientist awards and 6 Scholarship/Scientist awards from other peer reviewed agencies. Dr Harvey Lui stepped down as Associate Head of Medicine, UBC and Vancouver Acute, on August 31, 2005. I wish to express a sincere thank you to Harvey for all his efforts on behalf of myself and the department. I am pleased to announce that Dr Michael Barnett was appointed Associate Head of Medicine, UBC and Vancouver Acute effective September 1, 2005. I am particularly pleased to announce the appointment of Dr Janet McElhaney, Head, UBC Division of Geriatric Medicine from October 1, 2005. Dr. McElhaney received her medical training at the University of Alberta and completed her residency in Internal Medicine and Geriatric Medicine at that institution. She was previously on staff at the University of Connecticut Health Centre, in Hartford. Dr John Fleetham stepped down as Division Head for the UBC Division of Respiratory Medicine on June 30, 2005. His stewardship and support of departmental priorities have been exemplary and I wish to express a sincere thank you for all his efforts on behalf of myself and the department. Dr Paul Man was appointed Acting Head, UBC Division of Respiratory Medicine July 1, 2005. Awards The Department extends its warmest congratulations to these outstanding individuals who received the following Departmental awards: The Fay R. Dirks Awards for Excellence in Teaching were awarded to Drs. Roger Wong (Geriatric Medicine) and Rose Hatala (General Internal Medicine); The Martin M. Hoffman Awards for Excellence in Research were awarded to Drs. Diane Lacaille (Rheumatology) and Don Sin (Respiratory); The Donald M. Whitelaw Awards for Outstanding Grand Rounds were given to Drs. Heather Finlayson, Andrew Travlos & Russell O’Connor (Physical Medicine & Rehabilitation) and Julio Montaner (Infectious Diseases); The Master Teacher Awards were given to Drs. Jeff Beckman (Neurology) and Barry Kassen (General Internal Medicine). In addition, members of the department were recognized by the faculty and other bodies for their excellence in teaching and research: Dr. G. B. John Mancini (Cardiology) was appointed an Elite Reviewer for the Journal of the American College of Cardiology; Dr. Dwight Peretz (Cardiology) was elected to Mastership by the Board of Regents of the American College of Physicians, Internal Medicine; Dr John Esdaile (Rheumatology) received the Canadian Rheumatology Association Distinguished Investigator Award; Dr Juan Ronco (Critical Care Medicine) received a commendation for contributions to the 2004 Acute Critical Events Simulation (ACES) Program; Dr Harvey Lui was elected as President of the Canadian Dermatology Association; Dr Alastair McLeod (Dermatology) was appointed as Honorary Member of the Canadian Medical Association; Dr Jolanda Cibere (Rheumatology) received the Networks of Centres of Excellence Young Innovators Award; Dr Gordon Page (General Internal Medicine) received a 2005 Award for Outstanding Achievement in the Evaluation of Clinical Competence by the Medical Council of Canada; Drs. Robert Brunham & Neil Reiner (Infectious Diseases) received a BC Genome Award; Dr Dean Johnston (Neurology) received the Roche UBC Department of Medicine Page 4 Annual Report 2005 Award for Excellence in Clinical Skills Teaching; Dr Hugh Chaun (Gastroenterology) received an Award of Excellence of the College of Physicians and Surgeons of BC; Dr Isabella Tai (Gastroenterology) was awarded a Michael Smith Foundation for Health Research Career Investigator Senior Scholar Award for Biomedical Research; Dr John Gill (Nephrology) was awarded a Michael Smith Foundation for Health Research Career Investigator Scholar Award for Health Sciences Research and a Michael Smith Clinical Investigator Award; Dr Jim Busser (General Internal Medicine) received the Bobby Miller Award for Excellence in Teaching; Dr Yu Tian Wang (Neurology) was awarded the UBC Killam Research Prize in Junior Science; Dr Peter Pare (Respiratory Medicine) was awarded the UBC Killam Research Prize in Senior Science; Dr Stephan van Eeden (Respiratory Medicine) received the William Thurlbeck Distinguished Researcher Award; Dr Kenneth Blocka (Rheumatology) received the Clinical Faculty Award for Excellence in Teaching; Dr Barry Koehler (Rheumatology) and Dr Ted Wilkins (Endocrinology) both received UBC Career Awards for Excellence in Teaching; and Dr Richard Klasa (Medical Oncology) received a PAR-BC Residents’ Advocate Award. One of the Department's most important strategic initiatives is the creation of the Academic Enhancement Endowment Fund and the Academic Enhancement Fund competition process. These awards are provided in an effort to ensure greater protected research time for individuals undertaking meritorious research. This fund has taken on greater importance as the endowment has grown and as the awards have increased. The recipients of the Academic Enhancement Endowment Fund awards in 2005 were Drs. Jason Barton (Neurology), Victoria Cook (Respiratory) and Sharlene Gill (Medical Oncology). Recipients are termed Departmental Scholars. Clinical The foundation of all activities in a Department of Medicine is exemplary patient care. Maintaining the highest quality of care has been challenging due to resource constraints, but our members continue to provide excellent care to the citizens of Vancouver and the province of British Columbia. The Regional Medical
Load more

Recommended publications
  • Guidelines for Transfusions
    Guidelines for Transfu- sion Prepared by: Community Transfusion Committee Lincoln, Nebraska CHAIR: Aina Silenieks, MD MEMBERS: L. Bausch, M.D. R. Burton, M.D. S. Dunder, M.D. D. Voigt, M.D. B. J. Wilson, M.D. COMMUNITY Becky Croner REPRESENTATIVES: Ellen DiSalvo Christa Engel Phyllis Ericson Kelly Gillaspie Pat Gilles Vic Grdina Jessica Henrichs Kelly Jensen Laurel McReynolds Christina Nickel Angela Novotny Kelley Thiemann Janet Wachter Jodi Wikoff Guidelines For Transfusion Community Transfusion Committee INTRODUCTION The Community Transfusion Committee is a multidisciplinary group that meets to monitor blood utilization practices, establish guidelines for transfusion and discuss relevant transfusion related topics. It is comprised of physicians from local hospitals, invited guests, and community representatives from the hospitals’ transfusion services, nursing services, perfusion services, health information management, and the Nebraska Community Blood Bank. These Guidelines for Transfusion are reviewed and revised biannually by the Community Trans- fusion Committee to ensure that the industry’s most current practices are promoted. The Guidelines are the standard by which utilization practices are evaluated. They are also de- signed to provide helpful information to assist physicians to provide appropriate blood compo- nent therapy to patients. Appendices have been added for informational purposes and are not to be used as guidance for clinical decision making. ADULT RED CELLS A. Indications 1. One of the following a. Hypovolemia and hypoxia (signs/symptoms: syncope, dyspnea, postural hypoten- sion, tachycardia, angina, or TIA) secondary to surgery, trauma, GI tract bleeding, or intravascular hemolysis, OR b. Evidence of acute loss of 15% of total blood volume or >750 mL blood loss, OR c.
    [Show full text]
  • 27. Clinical Indications for Cryoprecipitate And
    27. CLINICAL INDICATIONS FOR CRYOPRECIPITATE AND FIBRINOGEN CONCENTRATE Cryoprecipitate is indicated in the treatment of fibrinogen deficiency or dysfibrinogenaemia.1 Fibrinogen concentrate is licenced for the treatment of acute bleeding episodes in patients with congenital fibrinogen deficiency, including afibrinogenaemia and hypofibrinogenaemia,2 and is currently funded under the National Blood Agreement. Key messages y Fibrinogen is an essential component of the coagulation system, due to its role in initial platelet aggregation and formation of a stable fibrin clot.3 y The decision to transfuse cryoprecipitate or fibrinogen concentrate to an individual patient should take into account the relative risks and benefits.3 y The routine use of cryoprecipitate or fibrinogen concentrate is not advised in medical or critically ill patients.2,4 y Cryoprecipitate or fibrinogen concentrate may be indicated in critical bleeding if fibrinogen levels are not maintained using FFP. In the setting of major obstetric haemorrhage, early administration of cryoprecipitate or fibrinogen concentrate may be necessary.3 Clinical implications y The routine use of cryoprecipitate or fibrinogen concentrate in medical or critically ill patients with coagulopathy is not advised. The underlying causes of coagulopathy should be identified; where transfusion is considered necessary, the risks and benefits should be considered for each patient. Specialist opinion is advised for the management of disseminated intravascular coagulopathy (MED-PP18, CC-PP7).2,4 y Cryoprecipitate or fibrinogen concentrate may be indicated in critical bleeding if fibrinogen levels are not maintained using FFP. In patients with critical bleeding requiring massive transfusion, suggested doses of blood components is 3-4g (CBMT-PP10)3 in adults or as per the local Massive Transfusion Protocol.
    [Show full text]
  • Cryosupernatant Plasma
    Cryosupernatant Plasma APPLICABILITY: This document applies to Other Names: Cryopoor Plasma AHS, Covenant Health, and all other health Class: Human blood component care professionals involved in the transfusion of blood components and products in Alberta INTRAVENOUS OTHER Intermittent Continuous ROUTES DIRECT IV SC IM OTHER Infusion Infusion Acceptable No Yes No No No N/A Routes* * Professionals performing these restricted activities have received authorization from their regulatory college and have the knowledge and skill to perform the skill competently. DESCRIPTION OF PRODUCT: . Cryosupernatant Plasma (CSP) is prepared from slowly thawed Frozen Plasma that is centrifuged to separate the insoluble cryopreciptate from the plasma. The remaining Cryosupernatant plasma is then refrozen. The approximate volume of a unit is 273 mL . CSP has reduced levels of Factor VIII and von Willebrand Factor (vWF), and does not contain measurable amounts of Factor VIII or fibrinogen. Donors are screened and blood donations are tested for: . ABO/Rh and clinically significant antibodies . Antibodies to human immunodeficiency virus (HIV-1 and HIV-2), hepatitis C virus (HCV), human T-cell lymphotropic virus type I and II (HTLV-I/II), hepatitis B core antigen (HBcore) . Hepatitis B Surface Antigen (HBsAg) . Presence of viral RNA (HIV-1 and HCV) and viral DNA (hepatitis B virus (HBV)) . Syphilis AVAILABILITY: . Not all laboratories/transfusion services stock CSP. Product is stored frozen, and as a result requires preparation time prior to issuing. Patient blood type should be determined when possible to allow for ABO specific/compatible plasma transfusion INDICATIONS FOR USE: . Plasma exchange in patients with Thrombotic Thrombocytopenic Purpura (TTP) or Hemolytic Uremic Syndrome (HUS).
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 7.803,838 B2 Davis Et Al
    USOO7803838B2 (12) United States Patent (10) Patent No.: US 7.803,838 B2 Davis et al. (45) Date of Patent: Sep. 28, 2010 (54) COMPOSITIONS COMPRISING NEBIVOLOL 2002fO169134 A1 11/2002 Davis 2002/0177586 A1 11/2002 Egan et al. (75) Inventors: Eric Davis, Morgantown, WV (US); 2002/0183305 A1 12/2002 Davis et al. John O'Donnell, Morgantown, WV 2002/0183317 A1 12/2002 Wagle et al. (US); Peter Bottini, Morgantown, WV 2002/0183365 A1 12/2002 Wagle et al. (US) 2002/0192203 A1 12, 2002 Cho 2003, OOO4194 A1 1, 2003 Gall (73) Assignee: Forest Laboratories Holdings Limited 2003, OO13699 A1 1/2003 Davis et al. (BM) 2003/0027820 A1 2, 2003 Gall (*) Notice: Subject to any disclaimer, the term of this 2003.0053981 A1 3/2003 Davis et al. patent is extended or adjusted under 35 2003, OO60489 A1 3/2003 Buckingham U.S.C. 154(b) by 455 days. 2003, OO69221 A1 4/2003 Kosoglou et al. 2003/0078190 A1* 4/2003 Weinberg ...................... 514f1 (21) Appl. No.: 11/141,235 2003/0078517 A1 4/2003 Kensey 2003/01 19428 A1 6/2003 Davis et al. (22) Filed: May 31, 2005 2003/01 19757 A1 6/2003 Davis 2003/01 19796 A1 6/2003 Strony (65) Prior Publication Data 2003.01.19808 A1 6/2003 LeBeaut et al. US 2005/027281.0 A1 Dec. 8, 2005 2003.01.19809 A1 6/2003 Davis 2003,0162824 A1 8, 2003 Krul Related U.S. Application Data 2003/0175344 A1 9, 2003 Waldet al. (60) Provisional application No. 60/577,423, filed on Jun.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 8.598,119 B2 Mates Et Al
    US008598119B2 (12) United States Patent (10) Patent No.: US 8.598,119 B2 Mates et al. (45) Date of Patent: Dec. 3, 2013 (54) METHODS AND COMPOSITIONS FOR AOIN 43/00 (2006.01) SLEEP DSORDERS AND OTHER AOIN 43/46 (2006.01) DSORDERS AOIN 43/62 (2006.01) AOIN 43/58 (2006.01) (75) Inventors: Sharon Mates, New York, NY (US); AOIN 43/60 (2006.01) Allen Fienberg, New York, NY (US); (52) U.S. Cl. Lawrence Wennogle, New York, NY USPC .......... 514/114: 514/171; 514/217: 514/220; (US) 514/229.5: 514/250 (58) Field of Classification Search (73) Assignee: Intra-Cellular Therapies, Inc. NY (US) None See application file for complete search history. (*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 (56) References Cited U.S.C. 154(b) by 215 days. U.S. PATENT DOCUMENTS (21) Appl. No.: 12/994,560 6,552,017 B1 4/2003 Robichaud et al. 2007/0203120 A1 8, 2007 McDevitt et al. (22) PCT Filed: May 27, 2009 FOREIGN PATENT DOCUMENTS (86). PCT No.: PCT/US2O09/OO3261 S371 (c)(1), WO WOOOf77OO2 * 6, 2000 (2), (4) Date: Nov. 24, 2010 OTHER PUBLICATIONS (87) PCT Pub. No.: WO2009/145900 Rye (Sleep Disorders and Parkinson's Disease, 2000, accessed online http://www.waparkinsons.org/edu research/articles/Sleep PCT Pub. Date: Dec. 3, 2009 Disorders.html), 2 pages.* Alvir et al. Clozapine-Induced Agranulocytosis. The New England (65) Prior Publication Data Journal of Medicine, 1993, vol. 329, No. 3, pp. 162-167.* US 2011/0071080 A1 Mar.
    [Show full text]
  • Guidelines for Transfusion and Patient Blood Management, and Discuss Relevant Transfusion Related Topics
    Guidelines for Transfusion and Community Transfusion Committee Patient Blood Management Community Transfusion Committee CHAIR: Aina Silenieks, M.D., [email protected] MEMBERS: A.Owusu-Ansah, M.D. S. Dunder, M.D. M. Furasek, M.D. D. Lester, M.D. D. Voigt, M.D. B. J. Wilson, M.D. COMMUNITY Juliana Cordero, Blood Bank Coordinator, CHI Health Nebraska Heart REPRESENTATIVES: Becky Croner, Laboratory Services Manager, CHI Health St. Elizabeth Mackenzie Gasper, Trauma Performance Improvement, Bryan Medical Center Kelly Gillaspie, Account Executive, Nebraska Community Blood Bank Mel Hanlon, Laboratory Specialist - Transfusion Medicine, Bryan Medical Center Kyle Kapple, Laboratory Quality Manager, Bryan Medical Center Lauren Kroeker, Nurse Manager, Bryan Medical Center Christina Nickel, Clinical Laboratory Director, Bryan Medical Center Rachael Saniuk, Anesthesia and Perfusion Manager, Bryan Medical Center Julie Smith, Perioperative & Anesthesia Services Director, Bryan Medical Center Elaine Thiel, Clinical Quality Improvement/Trans. Safety Officer, Bryan Med Center Kelley Thiemann, Blood Bank Lead Technologist, CHI Health St. Elizabeth Cheryl Warholoski, Director, Nebraska Operations, Nebraska Community Blood Bank Jackie Wright, Trauma Program Manager, Bryan Medical Center CONSULTANTS: Jed Gorlin, M.D., Innovative Blood Resources [email protected] Michael Kafka, M.D., LifeServe Blood Center [email protected] Alex Smith, D.O., LifeServe Blood Center [email protected] Nancy Van Buren, M.D., Innovative
    [Show full text]
  • 5-HT Receptor Agonist Befiradol Reduces Fentanyl-Induced
    5-HT1A Receptor Agonist Befiradol Reduces Fentanyl-induced Respiratory Depression, Analgesia, and Sedation in Rats Jun Ren, Ph.D., Xiuqing Ding, B.Sc., John J. Greer, Ph.D. ABSTRACT Background: There is an unmet clinical need to develop a pharmacological therapy to counter opioid-induced respiratory depression without interfering with analgesia or behavior. Several studies have demonstrated that 5-HT1A receptor agonists alleviate opioid-induced respiratory depression in rodent models. However, there are conflicting reports regarding their effects on analgesia due in part to varied agonist receptor selectivity and presence of anesthesia. Therefore the authors performed a Downloaded from http://pubs.asahq.org/anesthesiology/article-pdf/122/2/424/267207/20150200_0-00031.pdf by guest on 27 September 2021 study in rats with befiradol (F13640 and NLX-112), a highly selective 5-HT1A receptor agonist without anesthesia. Methods: Respiratory neural discharge was measured using in vitro preparations. Plethysmographic recording, nociception testing, and righting reflex were used to examine respiratory ventilation, analgesia, and sedation, respectively. Results: Befiradol (0.2 mg/kg, n = 6) reduced fentanyl-induced respiratory depression (53.7 ± 5.7% of control minute ven- tilation 4 min after befiradol vs. saline 18.7 ± 2.2% of control, n = 9; P < 0.001), duration of analgesia (90.4 ± 11.6 min vs. saline 130.5 ± 7.8 min; P = 0.011), duration of sedation (39.8 ± 4 min vs. saline 58 ± 4.4 min; P = 0.013); and induced baseline hyperventilation, hyperalgesia, and “behavioral syndrome” in nonsedated rats. Further, the befiradol-induced alleviation of opioid-induced respiratory depression involves sites or mechanisms not functioning in vitro brainstem–spinal cord and medul- lary slice preparations.
    [Show full text]
  • Modifications to the Harmonized Tariff Schedule of the United States To
    U.S. International Trade Commission COMMISSIONERS Shara L. Aranoff, Chairman Daniel R. Pearson, Vice Chairman Deanna Tanner Okun Charlotte R. Lane Irving A. Williamson Dean A. Pinkert Address all communications to Secretary to the Commission United States International Trade Commission Washington, DC 20436 U.S. International Trade Commission Washington, DC 20436 www.usitc.gov Modifications to the Harmonized Tariff Schedule of the United States to Implement the Dominican Republic- Central America-United States Free Trade Agreement With Respect to Costa Rica Publication 4038 December 2008 (This page is intentionally blank) Pursuant to the letter of request from the United States Trade Representative of December 18, 2008, set forth in the Appendix hereto, and pursuant to section 1207(a) of the Omnibus Trade and Competitiveness Act, the Commission is publishing the following modifications to the Harmonized Tariff Schedule of the United States (HTS) to implement the Dominican Republic- Central America-United States Free Trade Agreement, as approved in the Dominican Republic-Central America- United States Free Trade Agreement Implementation Act, with respect to Costa Rica. (This page is intentionally blank) Annex I Effective with respect to goods that are entered, or withdrawn from warehouse for consumption, on or after January 1, 2009, the Harmonized Tariff Schedule of the United States (HTS) is modified as provided herein, with bracketed matter included to assist in the understanding of proclaimed modifications. The following supersedes matter now in the HTS. (1). General note 4 is modified as follows: (a). by deleting from subdivision (a) the following country from the enumeration of independent beneficiary developing countries: Costa Rica (b).
    [Show full text]
  • Yasakli Maddeler
    YASAKLI MADDELER Ülkemizde yarış atlarında kullanılan/kullanılma ihtimali olan ilaçların/maddelerin belirlenmesinde; ilacın farmakolojisi (öncelikle etkisi, etki grubu), farmasötik şekli, kullanılma yolu, kullanılma alanı, yarış sonucunu etkileme durumu, ulusal mevzuata göre veteriner hekimlikte ve/veya yarış atlarında kullanmak için ruhsatlı/izinli olup-olmama durumu, etiket-dışı kullanılma gibi hususlar dikkate alınmıştır. Eşik değeri (Threshold level) olan maddelerin (vücutta şekillenirler, çevre ve yem kaynaklı olabilirler) miktarı, belirlenen miktarı aştığında yasaklı-madde kullanılması/doping ihlali olarak değerlendirilir. Tedavide kullanılan/tarama limiti (Screening level) olan maddelerle ilgili değerlendirmede; bu maddelerle ilgili olarak yapılan doping analizlerinde ölçülen miktar, idrarda/plazmada belirlenen tarama değerini aştığında yasaklı madde kullanılması/doping-ihlali olarakdeğerlendirilir. Ana madde yanında, izomeri, metaboliti, metabolit izomeri, tuzları, esterleri, eterleri, diğer türevleri, ön-ilaç da yasaklı-madde listesinde yer alır; doping analizinde ortaya konulmaları doping ihlali olarak değerlendirilir. Maddeler ve yasaklı uygulamalar 6 başlık altında toplanmıştır. Bu liste ilgili uluslararası kuruluşların mevzuat ve düzenlemeleri ile ilgili maddelerin Farmakolojik özellikleri ve etkileri dikkate alınarak hazırlanmıştır. 1. YasaklıMaddeler Yasaklı maddeler; yarış atlarında tıbbi olarak kullanım yeri olmayan, atın yarış performansını açık şekilde etkileyen maddelerdir. İllegal kullanılan maddeler (Türkiye’de veteriner
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2015/0072964 A1 Mates Et Al
    US 20150.072964A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2015/0072964 A1 Mates et al. (43) Pub. Date: Mar. 12, 2015 (54) NOVELMETHODS filed on Apr. 14, 2012, provisional application No. 61/624.293, filed on Apr. 14, 2012, provisional appli (71) Applicant: INTRA-CELLULAR THERAPIES, cation No. 61/671,713, filed on Jul. 14, 2012, provi INC., New York, NY (US) sional application No. 61/671,723, filed on Jul. 14, 2012. (72) Inventors: Sharon Mates, New York, NY (US); Robert Davis, New York, NY (US); Publication Classification Kimberly Vanover, New York, NY (US); Lawrence Wennogle, New York, (51) Int. Cl. NY (US) C07D 47L/6 (2006.01) A613 L/4985 (2006.01) (21) Appl. No.: 14/394,469 A6II 45/06 (2006.01) (52) U.S. Cl. (22) PCT Fled: Apr. 14, 2013 CPC .............. C07D 471/16 (2013.01); A61K 45/06 (2013.01); A61 K3I/4985 (2013.01) (86) PCT NO.: PCT/US13A36512 USPC ...... 514/171; 514/250; 514/211.13: 514/217; S371 (c)(1), 514/214.02: 514/220 (2) Date: Oct. 14, 2014 (57) ABSTRACT Use of particular substituted heterocycle fused gamma-car Related U.S. Application Data boline compounds as pharmaceuticals for the treatment of (60) Provisional application No. 61/624.291, filed on Apr. agitation, aggressive behaviors, posttraumatic stress disorder 14, 2012, provisional application No. 61/624,292, or impulse control disorders. US 2015/0072964 A1 Mar. 12, 2015 NOVEL METHODS One type of ICD is Intermittent Explosive Disorder (IED) which involves violence or rage. There is a loss of control CROSS REFERENCE TO RELATED grossly out of proportion to any precipitating psychosocial APPLICATIONS stresses.
    [Show full text]
  • Guide to Blood Plasma Products and Their Applications – Part One
    Vet Times The website for the veterinary profession https://www.vettimes.co.uk Guide to blood plasma products and their applications – part one Author : Amanda Boag, Jenny Walton Categories : Vets Date : September 26, 2011 Amanda Boag and Jenny Walton discuss indications for the use of plasma products, their production, and storage within the practice in the first of a three-part series FOLLOWING changes in legislation in 2005, veterinary blood banking and component therapy has developed rapidly within the UK. Practitioners now have easy access to canine blood and its products – notably, packed red cells and various plasma products. This series of articles will focus on indications for plasma product use, their production and storage, the administration and monitoring of plasma transfusions and will include a series of five case studies that have used plasma products. Indications for plasma component therapy Although well-defined indications exist for the use of plasma products in single or multiple coagulation deficiencies, indications for many of its other uses are empiric. Haemostatic disorders Plasma components are most commonly used to treat haemostatic disorders and are generally effective in treating both inherited and acquired conditions. Specific diagnosis enables selection of the optimum replacement product. It is important to remember that any samples drawn for diagnostic purposes (for example, measurement of clotting factor levels) must be taken either 1 / 5 before or at least 36 hours after transfusion to allow the measurement of endogenous levels. Inherited bleeding disorders Plasma components are administered to control active haemorrhage or as preoperative prophylaxis. Inherited bleeding disorders are associated with deficiency of a specific factor and the optimal product for treatment depends on which factor is lacking.
    [Show full text]
  • Understanding History, and Not Repeating It. Neuroprotection For
    Clinical Neurology and Neurosurgery 129 (2015) 1–9 Contents lists available at ScienceDirect Clinical Neurology and Neurosurgery jo urnal homepage: www.elsevier.com/locate/clineuro Review Understanding history, and not repeating it. Neuroprotection for acute ischemic stroke: From review to preview a a b b,c a,b,c,d,∗ Stephen Grupke , Jason Hall , Michael Dobbs , Gregory J. Bix , Justin F. Fraser a Department of Neurosurgery, University of Kentucky, Lexington, USA b Department of Neurology, University of Kentucky, Lexington, USA c Department of Anatomy and Neurobiology, University of Kentucky, Lexington, USA d Department of Radiology, University of Kentucky, Lexington, USA a r t i c l e i n f o a b s t r a c t Article history: Background: Neuroprotection for ischemic stroke is a growing field, built upon the elucidation of the Received 17 April 2014 biochemical pathways of ischemia first studied in the 1970s. Beginning in the early 1990s, means by Received in revised form 7 November 2014 which to pharmacologically intervene and counteract these pathways have been sought, though with Accepted 13 November 2014 little clinical success. Through a comprehensive review of translations from laboratory to clinic, we aim Available online 3 December 2014 to evaluate individual mechanisms of action, while highlighting potential barriers to success that will guide future research. Keywords: Methods: The MEDLINE database and The Internet Stroke Center clinical trials registry were queried Acute stroke Angiography for trials involving the use of neuroprotective agents in acute ischemic stroke in human subjects. For the purpose of the review, neuroprotective agents refer to medications used to preserve or protect the Brain ischemia Drug trials potentially ischemic tissue after an acute stroke, excluding treatments designed to re-establish perfusion.
    [Show full text]